{"id":30982,"date":"2022-04-19T15:35:11","date_gmt":"2022-04-19T14:35:11","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&p=30982"},"modified":"2022-04-19T15:38:55","modified_gmt":"2022-04-19T14:38:55","slug":"stewart-tepper-aan-2022-limitations-of-current-treatments-for-acute-migraine","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/headache-disorders\/conference-hub\/stewart-tepper-aan-2022-limitations-of-current-treatments-for-acute-migraine\/","title":{"rendered":"Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine"},"content":{"rendered":"

The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability.<\/span> Prof. Stewart Tepper<\/b> (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these.<\/span><\/p>\n

The abstract entitled \u2018<\/span>Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3, Randomized, Double-blind, Active- and Placebo-controlled Trial<\/b><\/a>\u2019 was presented at the <\/span>American Academy of Neurology (AAN)<\/span><\/a> annual meeting, April 2-7, 2022.<\/span><\/p>\n

Question:<\/b><\/p>\n

    \n
  1. What are the limitations of current treatments for acute migraine and how do new treatments overcome these? (0:20)<\/span><\/li>\n<\/ol>\n

    Disclosures<\/b>: Stewart Tepper has received grants for research (no personal compensation) from Allergan\/Abbvie, Amgen, Eli Lilly, Lundbeck, Neurolief, Novartis, Satsuma, and Zosano; and has received consultant and\/or advisory board honoraria from Aeon, Allergan\/Abbvie, Alphasights, Amgen, Aruene, Atheneum, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, ClearView Healthcare Partners, CoolTech, CRG, Currax, Decision Resources, Defined Health, DRG, Eli Lilly, ExpertConnect, FCB Health, Fenix, GLG, Guidepoint Global, Health Advances, Health Science Communications, HMP Communications, Impel, InteractiveForums, Keyquest, Krog and Partners, Lundbeck, M3 Global Research, Magnolia Innovation, MJH Holdings, Neurolief, Novartis, P Value Communications, Pain Insights, Inc,\u00a0 Palion Medical, Pulmatrix, Putnam Associates, SAI MedPartners, Satsuma, Slingshot Insights, Spherix Global Insights, Strategy Inc, System Analytic, Taylor and Francis, Teva, Theranica, Tremeau, Trinity Partners, Unity HA, XOC, Zosano<\/span><\/p>\n

    Stewart Tepper has received CME honoraria from American Academy of Neurology, American Headache Society, Annenberg Center for Health Sciences, Catamount Medical Education, Diamond Headache Clinic, Forefront Collaborative, Haymarket Medical Education, Medical Education Speakers Network, Medical Learning Institute Peerview, Migraine Association of Ireland, Miller Medical Education, National Association for Continuing Education, North American Center for CME, The Ohio State University, Physicians\u2019 Education Resource, PlatformQ Education, Primed, Texas Neurological Society, Vindico Medical Education and WebMD\/Medscape.<\/span><\/p>\n

    Support<\/b>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/span><\/p>\n

    Filmed as a highlight of AAN 2022<\/i><\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled \u2018Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]<\/p>\n","protected":false},"featured_media":30978,"template":"","class_list":["post-30982","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-headache-disorders","video_categories-aan-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/30982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":4,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/30982\/revisions"}],"predecessor-version":[{"id":30986,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/30982\/revisions\/30986"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/30978"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=30982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}